The goal of the trial, known as HIV-CORE 0052, is to evaluate the safety, tolerability, and immunogenicity of the HIVconsvX vaccine – a mosaic vaccine targeting a broad range of HIV-1 variants, making it potentially applicable for HIV strains in any geographical region.
Thirteen healthy, HIV-negative adults, aged 18-65 and who are considered not to be at high risk of infection, will initially receive one dose of the vaccine followed by a further booster dose at four weeks.
- Read more about HIV vaccine trial starts at Oxford
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2021/hiv-vaccine-trial-starts-at-oxford
No comments:
Post a Comment